WCM
FATE icon

Weld Capital Management’s Fate Therapeutics FATE Stock Holding History

Weld Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-17,998
Closed -$618K – 542
2020
Q2 		$618K Buy
+17,998
New +$536K 0.24% 147
2019
Q4 		– Sell
-75,227
Closed -$1.17M – 707
2019
Q3 		$1.17M Buy
+75,227
New +$1.44M 0.21% 123

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Weld Capital Management's FATE Position: Q3 2020 in Review

Weld Capital Management sold out of Fate Therapeutics (FATE) in Q3 2020, closing a stake of 17,998 shares — an estimated $618K sold.

Weld Capital Management first reported a position in FATE in Q3 2019 and held it in 2 quarters. The position peaked at $1.17M in Q3 2019. 211 funds tracked by Wall St. Rank hold FATE as of Q3 2020.

  • Weld Capital Management reported no remaining Fate Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Weld Capital Management sold 17,998 Fate Therapeutics shares in Q3 2020, an estimated $618K.
  • Weld Capital Management first reported a position in Fate Therapeutics in Q3 2019 and held it in 2 quarters.
  • Weld Capital Management's Fate Therapeutics position peaked at $1.17M in Q3 2019.
  • 211 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2020.

Based on Weld Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.